In this Thought Leaders podcast, brought to you by SAVVIS, Andy Schroepfer, president & founder of Tier 1 Research, discusses his view on the hosting industry, including the market forecast and segmentation, future growth areas, and how the buyer — [See the full post…]

Jim Jones is a managing director at Scale Venture Partners, a venture capital firm which invests in emerging tech and healthcare companies. Jim’s focus is on semiconductors and consumer electronics, so we met with him last week at CES to [See the full post…]

Gary Kennedy, one of the first 10 employees at Oracle, has a new home as CEO of RemedyMD, a health care informatics and decision support sevice for practitioners, researchers, and patients. Kennedy says it’s crazy that retailers can tell you [See the full post…]

In his keynote, Louis Burns, vice president and general manager of Intel’s digital health group, delivered an impassioned appeal for health care solutions to developers at IDF Fall 2006 in San Francisco. More information from IDF Intel Digital Health Group’s [See the full post…]

Tengion is a leader in the field of regenerative medicine, developing new human tissues and organs derived from a patient’s own cells. Tengion’s patented technology has the potential to allow adults and children with organ failure to have functioning organs [See the full post…]

Despite President Bush’s veto of the embryonic stem cell bill almost two months ago, many venture capitalists consider the stem cell market to be viable… though just not yet for some investors. When and why will a venture capitalist invest [See the full post…]

Venture capitalist Andy Kessler says silicon is going to do to the health care industry what it has done to portable devices and the Internet. Where will it start? With diagnostics, according to Kessler, who delivered the lunch keynote at [See the full post…]

Getting money for a Series B round in health care deals results in a “down round” at least 50 percent of the time. Ralph (Chris) Christoffersen, a general partner at Morgenthaler Ventures, tells PodTech’s Jennifer Jones how his firm helps [See the full post…]

Patients desire improved treatments, voters call for safety, biomed startups want drug approval to continue in business and big pharma is after big profits. The Food and Drug Administration must grapple with these issues, which are only getting more complex. [See the full post…]

The U.S. Food and Drug Administration says it is a constant balancing act to determine how much risk to consumers is acceptable in the drug approval process. No risk would result in few drugs coming to market. Some risk allows [See the full post…]

Many exciting biomed startups have found a home in the venture capital market. “Public investors are risk averse these days,” says VentureWire’s Tom Salemi. “They only want to bet on as sure a thing as possible. That’s not usually the [See the full post…]

Change is coming fast for health care investors, executives and entrepreneurs. Public investors have rejected companies built on once-surefire models. Big Pharma, after years of nibbling, is acquiring private drug companies to boost internal pipelines. IT may finally be making [See the full post…]

Famed Analyst, Investor and Silicon Valley Guru, Andy Kessler on the “End of Medicine”. Andy Kessler, the guy behind the books Wall Street Meat and Running Money, just published a new book End of Medicine. Andy, who has been a [See the full post…]

Michael Johnson sits down with Jason Rushforth, General Manager of Financial Services and Health Care Vertical at Pivotal, to talk about customer relationship management (CRM). Click here for transcript

Juniper has designated David Weiner as a Master of IT. David talks about operating a non-profit corporation and the challenges of IT within a combined health care company. This Juniper Networks podcast is part of the Juniper Networks Master of [See the full post…]